Relvar Ellipta: GlaxoSmithKline and Theravance’s Drug for Respiratory Diseases

Relvar Ellipta: Over the past few days, research-based pharmaceutical GlaxoSmithKline plc (ADR) (NYSE:GSK) and biopharmaceutical company Theravance Inc (NASDAQ:THRX)’s Relvar Ellipta has been in the news. This is the proposed proprietary name for FF/VI 100/25 – 200/25 mcg, a combination of the inhaled corticosteroid (ICS) fluticasone furoate “FF” and the long acting bronchodilator (LABA) vilanterol “VI” (FF/VI). Both dosages are administered once-daily using the Ellipta, a new dry powder inhaler (DPI), making it the first once-daily, inhaled drug of its kind.

GlaxoSmithKline plc (ADR) (NYSE:GSK)

Recently, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of their candidate Relvar Ellipta in the EU. By the end of the year a final decision is expected to be made.

The CHMP recommended the approval of Relvar Ellipta only for the regular treatment of asthma in adults and adolescents –aged above 12 years. This treatment is only recommended in cases where a combination therapy is appropriate. For patients who suffer a asthma that is not sufficiently controlled with inhaled corticosteroids and short-acting inhaled beta 2-agonists the drug has been also recommended. Also, the CHMP backed the drug for the symptomatic treatment of adults suffering from chronic obstructive pulmonary disease (COPD) –term referring to chronic bronchitis and emphysema.

A day after the drug received its recommendation from the EU, Relvar Ellipta received approval also by the Japanese Ministry of Health, Labor and Welfare, for the treatment of bronchial asthma. Here it has only been approved for cases where the parallel use of inhaled corticosteroid and long-acting inhaled beta2 agonist is required. The drug has not been approved to treat COPD. This is contrary to the status the drug possesses in the US, where it can be used to treat COPD –the third most common cause of dead- and not asthma. Subsequent to Japan’s decision, Theravance will make a milestone payment of $10 million to GlaxoSmithKline, as established on their collaboration agreement.

Last May, Theravance’s pipeline programs in collaboration with GlaxoSmithKline already received the approval of another drug, Brea Ellipta, a long term maintenance therapy of airflow obstruction and for patients suffering COPD, in the US and Canada. Although Relvar Ellipta has not been licensed or approved anywhere outside Japan for asthma treatment, it may be likely to be.

Disclosure: Pamela Gaviño holds no position in any stocks mentioned

Recommended Reading:

Is the Tide About to Turn in the Fight Against Chronic Lymphocytic Leukemia?

Could a Pair of Respiratory Disease Treatments Save This Big Pharma?

Will This Fishy Biotech Go Belly Up?

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

On the Move: The 10 Fastest Growing Businesses in 2015

Fast Money: The 10 Highest Paying Fast Food Restaurants

Mixing It Up: The 14 Best Music Mashups of 2014

Rito Pls Buff: The 10 Least Played Champions in LoL Season 4

10 Covers of Popular Songs that are Better than the Originals

Must See TV: The 9 Most Anticipated Shows of 2015

The 15 Biggest Box Office Bombs of All Time

10 Things The World Can’t Stand About Americans

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!